Vahhab Piranfar
  • Home
  • Projects
  • Learning
  • Discuss & Review
  • About
  • Publications
Categories
All (13)
Antibiotic PK/PD (11)
Bacterial Genetics (2)
Learning (13)

Learning

Short lessons on antibiotic PK/PD modeling and the bacterial genetics that shape resistance phenotypes used in simulation.

Tutorials · Modeling intuition · Not clinical advice

Short, plain-language notes on antibiotic exposure, target attainment, and the bacterial biology that turns genotype into the phenotypes we simulate. Written for people who build or read PK/PD models.

Learning tracks

Primary track

Antibiotic PK/PD essentials

MIC and indices, PTA/CFR, free drug, infusion mode, joint BL/BLI targets, provenance, effect site, renal strata, inoculum effect, and a CAZ-AVI style case.

Secondary track

Bacterial genetics for modelers

Chromosome versus plasmid resistance and HGT-driven MIC ecology, as annotations on the phenotype layer PK/PD actually uses.

Lessons

PK/PD targets and the MIC: what the indices actually mean

Learning
Antibiotic PK/PD

A plain-language primer on MIC, fT>MIC, AUC/MIC, and Cmax/MIC, and how to pick an index that matches the biology you are modeling.

Aug 30, 2026
5 min

PTA, CFR, and virtual populations

Learning
Antibiotic PK/PD

How Monte Carlo PK/PD simulations turn parameter variability into probability of target attainment and cumulative fraction of response.

Sep 3, 2026
5 min

Resistance, tolerance, and persistence in PK/PD language

Learning
Antibiotic PK/PD

Separate genetic resistance from tolerance and persistence, and see why a good-looking MIC-based PTA can still miss the mechanism of failure.

Sep 7, 2026
5 min

Chromosome vs plasmid resistance for PK/PD modelers

Learning
Bacterial Genetics

How chromosomal and plasmid-borne resistance change the meaning of an MIC input, and what should stay fixed versus mobile in a pharmacometric scenario.

Sep 11, 2026
5 min

Free drug and protein binding

Learning
Antibiotic PK/PD

Why unbound concentration matters for antibiotic PK/PD targets, and how a small binding mistake can quietly inflate PTA.

Sep 15, 2026
4 min

Intermittent vs continuous infusion for beta-lactams

Learning
Antibiotic PK/PD

How infusion mode reshapes concentration-time curves, and why fT>MIC or Css/MIC results change when the same daily dose is delivered differently.

Sep 19, 2026
4 min

Joint targets for beta-lactam / beta-lactamase inhibitor pairs

Learning
Antibiotic PK/PD

Why BL/BLI combinations need simultaneous success rules, and why averaging two separate PTA values is not joint target attainment.

Sep 23, 2026
4 min

Uncertainty and provenance in PK/PD evidence

Learning
Antibiotic PK/PD

How to keep Monte Carlo outputs honest when clearance, MIC weights, and targets come from fragmented published sources.

Sep 27, 2026
4 min

Horizontal gene transfer and MIC ecology

Learning
Bacterial Genetics

Why plasmid-mediated resistance makes MIC distributions time-sensitive, and how PK/PD modelers should treat epidemiology priors as perishable.

Oct 1, 2026
4 min

Effect site versus plasma: where the bug actually lives

Learning
Antibiotic PK/PD

Why plasma PK is a convenient proxy, when ELF, CSF, or tissue exposure changes the story, and how to keep site assumptions visible in a model.

Oct 5, 2026
5 min

Renal function and eGFR strata in antibiotic PK/PD

Learning
Antibiotic PK/PD

How kidney function reshapes clearance and attainment, and why virtual populations should treat eGFR classes as first-class scenario structure.

Oct 9, 2026
4 min

Inoculum effect: when bacterial density changes the drug story

Learning
Antibiotic PK/PD

Why some antibiotics look weaker against denser bacterial populations, and how modelers should treat inoculum as a scenario variable rather than a footnote.

Oct 13, 2026
4 min

Mini case: putting CAZ-AVI style PK/PD together

Learning
Antibiotic PK/PD

A walkthrough that connects free drug, joint targets, renal strata, provenance, and PTA into one ceftazidime-avibactam style modeling story.

Oct 17, 2026
5 min
No matching items

© 2026 Vahhab Piranfar — Molecular Microbiologist · Antimicrobial Resistance & Computational Modeling